ClinicalTrials.gg

Program

inobrodib

Also written as “CCS1477”, “Inobrodib” and “InoPd”.

Its studies are mostly in Multiple Myeloma · Breast Neoplasms · Hematologic Neoplasms, led by CellCentric.

Furthest: phase 3, since Aug 13, 20264 company-led studies, 3 open or runningNext primary completion: Mar 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CellCentric43 open or runningphase 3since Aug 13, 2026Jun 4, 2018Mar 31, 2027phase 2 · NCT04068597

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 4, 2018First study: phase 2 study in Breast NeoplasmsFirst studyNCT03568656 · 219 enrolled · United States, France, Netherlands and more
  2. Aug 12, 2019Phase 2 study in Hematologic NeoplasmsNCT04068597 · 250 planned · United States, France, Spain and more
  3. Jul 24, 2025Phase 2 study in Multiple Myeloma RefractoryNCT07096778 · 100 planned · United States, United Kingdom
  4. Aug 13, 2026Phase 3 study in Multiple Myeloma RefractoryPhase 3 reachedNCT07772024 · 450 planned · United States

Ahead

  1. Mar 31, 2027Primary completion: phase 2 study in Hematologic NeoplasmsNCT04068597
  2. Nov 2029Primary completion: phase 3 study in Multiple Myeloma RefractoryNCT07772024
  3. Dec 1, 2029Primary completion: phase 2 study in Multiple Myeloma RefractoryNCT07096778

TargetBeta

OPN1LW →read by rule
“An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), ”NCIt, by rule

Other programs on OPN1LW

ProgramCompanyFurthest phaseStudies
pocenbrodibrulepathos-ai-incphase 22

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07772024Multiple Myeloma Refractory · United States3RecruitingNov 2029450
NCT07096778Multiple Myeloma Refractory · United States, United Kingdom2RecruitingDec 1, 2029100
NCT04068597Hematologic Neoplasms · United States, France, Spain and more2RecruitingMar 31, 2027250
NCT03568656Breast Neoplasms · United States, France, Netherlands and more2CompletedJul 6, 2025219

How it is read

Names in the registry

  • “CCS1477”, 2 entries
  • “Inobrodib”, 1 entry
  • “InoPd”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.